ARTIVION, INC.
At today's price, ARTIVION, INC. (AORT) is priced for today's economics sustained for ~11.0 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Artivion sells implants and devices for aortic disease, a narrow surgical niche where its On-X mechanical heart valve and stent grafts grew 20% and 21% year over year in the most recent quarter, faster than the medical-device sector as a whole. [Source: Q1 CY2026 earnings release, May 7 2026] • The defining risk is the balance sheet behind the growth: trailing operating income covers interest only about 1.5 times, and the company just drew a $150 million term loan to fund the Endospan acquisit
Is AORT overvalued? See what's priced in →
230 institutional managers reported holding AORT in 13F filings for the quarter ended 2026-03-31. Together they hold about 89% of the company; the top 10 hold 48%. 30 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 1.9M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (2.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AORT's share count grew 23.4% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at AORT over the trailing three years: 2025: 2 buys totaling $53k. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AORT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -3.3% | -6.1% |
| 2023-11-04 | +10.5% | +17.7% |
| 2024-02-24 | +7.1% | +1.5% |
| 2024-05-08 | +13.6% | +11.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AORT's latest 8-K filings: 2026-05-18 (items 7.01, 8.01, 9.01); 2026-05-15 (items 5.07); 2026-05-07 (items 1.01, 2.02, 9.01); 2026-02-12 (items 2.02, 9.01); 2025-11-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 14, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.